Findings

What do systematic reviews say?

1,655 questions · 1,751 findings · 147 reviews · Pain, Palliative and Supportive Care

Sort:Best matchNewestHighest certainty Download CSV

No studies found 361 · 20.6%GRADE not reported 87 · 5%Very low 625 · 35.7%Low 367 · 21%Moderate 232 · 13.2%High 79 · 4.5%

Massage vs no massage

Anxiety (state) · cancer patients

1 finding from 1 review

Massage with or without aromatherapy for symptom relief in people with cancer 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 64 participants
Very low

Aromatherapy massage vs no massage

Bodily pain (SF‐8) ‐ medium‐term (> 4 weeks to < 8 weeks) · cancer patients

1 finding from 1 review

Massage with or without aromatherapy for symptom relief in people with cancer 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 86 participants
Very low

Aromatherapy massage vs no massage

Bodily pain (SF‐8) ‐ long‐term (≥ 8 weeks) · cancer patients

1 finding from 1 review

Massage with or without aromatherapy for symptom relief in people with cancer 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 86 participants
Very low

Oxycodone MR vs placebo

'Substantial benefit' (≥ 50% reduction in pain or PGIC very much improved) · adults with neuropathic pain (2 studies in peripheral diabetic neuropathy and 1 study in postherpetic neuralgia)

1 finding from 1 review

Oxycodone for neuropathic pain in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Oxycodone MR vs placebo

Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · adults with neuropathic pain (2 studies in peripheral diabetic neuropathy and 1 study in postherpetic neuralgia)

1 finding from 1 review

Oxycodone for neuropathic pain in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 537 participants
Very low

Oxycodone MR vs placebo

Withdrawals due to adverse events · adults with neuropathic pain (2 studies in peripheral diabetic neuropathy and 1 study in postherpetic neuralgia)

1 finding from 1 review

Oxycodone for neuropathic pain in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 680 participants
Very low

Oxycodone MR vs placebo

Lack of efficacy withdrawal · adults with neuropathic pain (2 studies in peripheral diabetic neuropathy and 1 study in postherpetic neuralgia)

1 finding from 1 review

Oxycodone for neuropathic pain in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 680 participants
Very low

Oxycodone MR vs placebo

Serious adverse events · adults with neuropathic pain (2 studies in peripheral diabetic neuropathy and 1 study in postherpetic neuralgia)

1 finding from 1 review

Oxycodone for neuropathic pain in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 352 participants
Very low

Oxycodone MR vs placebo

Death · adults with neuropathic pain (2 studies in peripheral diabetic neuropathy and 1 study in postherpetic neuralgia)

1 finding from 1 review

Oxycodone for neuropathic pain in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 680 participants
Very low

Intervention not reported

Breathlessness: change from baseline1 · adults with refractory breathlessness

1 finding from 1 review

Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness 2016 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 194 participants
Very low

Intervention not reported

Breathlessness: post‐treatment score1 · adults with refractory breathlessness

1 finding from 1 review

Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 7 participants
Very low

Intervention not reported

Breathlessness: post‐treatment score1 · adults with refractory breathlessness

1 finding from 1 review

Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness 2016 · Cochrane Headline outcomes only
no estimate extracted
12 studies · 338 participants
Low

Intervention not reported

Exercise tolerance: 6MWT5 ‐ total distance · adults with refractory breathlessness

1 finding from 1 review

Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 11 participants
Very low

Intervention not reported

Exercise tolerance: 6MWT5‐ change from baseline · adults with refractory breathlessness

1 finding from 1 review

Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 26 participants
Very low

Intervention not reported

Adverse events: constipation · adults with refractory breathlessness

It is very uncertain whether the intervention changes adverse events: constipation (very low certainty).

1 finding from 1 review

Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness 2016 · Cochrane Headline outcomes only
RR 3 [1.63, 5.51]
9 studies · 162 participants
Very low

Intervention not reported

Adverse events: nausea and vomiting · adults with refractory breathlessness

It is very uncertain whether the intervention changes adverse events: nausea and vomiting (very low certainty).

1 finding from 1 review

Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness 2016 · Cochrane Headline outcomes only
RR 4.73 [1.73, 12.97]
7 studies · 104 participants
Very low

Intervention not reported

Adverse events: drowsiness · adults with refractory breathlessness

It is very uncertain whether the intervention changes adverse events: drowsiness (very low certainty).

1 finding from 1 review

Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness 2016 · Cochrane Headline outcomes only
RR 2.86 [1.17, 7.02]
9 studies · 156 participants
Very low

Intervention not reported

Quality of life7 · adults with refractory breathlessness

1 finding from 1 review

Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Very low

Intervention not reported

Breathlessness: post‐treatment score1 · adults with refractory breathlessness

1 finding from 1 review

Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 63 participants
Very low

Breastfeeding vs other interventions, oral water, or no treatment

Duration of crying (seconds) · Infants 1 to 12 months during vaccination

1 finding from 1 review

Breastfeeding for procedural pain in infants beyond the neonatal period 2016 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 547 participants
Moderate